Business context and reporting period
argenx SE’s Form 20-F reports on the fiscal year ended December 31, 2021; it is an annual report, not a standalone fourth-quarter filing. The company is a commercial-stage biotechnology company focused on severe autoimmune diseases. Its financial statements are audited under IFRS and presented in U.S. dollars; comparative periods were retrospectively translated following the change in presentation currency from euros on January 1, 2021.
The FDA approved VYVGART (efgartigimod) for AChR-antibody-positive generalized myasthenia gravis (gMG) on December 17, 2021. The filing reports no product-sales revenue for 2021. Japan approved VYVGART after year-end, on January 20, 2022.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $497.3 million | $41.2 million |
| Research and development expense | $580.5 million | $370.9 million |
| Selling, general and administrative expense | $307.6 million | $171.6 million |
| Operating loss | $348.7 million | $477.6 million |
| Loss for the year | $408.3 million | $608.5 million |
| Total comprehensive loss | $450.6 million | $446.2 million |
| Operating cash flow | $(606.8) million | $(398.5) million |
| Cash and cash equivalents at year-end | $1,334.7 million | $1,216.8 million |
| Current financial assets at year-end | $1,002.1 million | $779.6 million |
Year-end total assets were $2.850 billion, equity was $2.534 billion, and total liabilities were $316.1 million. The company reported no financial debt; lease liabilities totaled $11.5 million. Current assets were $2.543 billion and current liabilities $301.2 million. No product gross margin is reported, and a product margin comparison is not meaningful because 2021 revenue was not from product sales.
Changes versus the prior year
- Revenue rose sharply, primarily from collaboration and license revenue recognized under the Zai Lab agreement and the termination of the Janssen collaboration—not from recurring product sales. The filing reports $292.3 million of Janssen-related upfront revenue and $151.9 million of Zai Lab-related upfront revenue, alongside milestone and service-fee revenue.
- Operating loss narrowed as collaboration revenue increased, even as R&D expense rose 57% and SG&A expense rose 79%, reflecting pipeline development and preparation for VYVGART commercialization.
- Net cash used in operations increased by $208.3 million. Financing cash inflow was $1.121 billion, largely from the February 2021 equity offering. Year-end cash, cash equivalents and current financial assets together totaled $2.337 billion.
- Total comprehensive loss was broadly similar to 2020 despite the lower loss for the year; 2021 included a $39.3 million fair-value loss on the Zai Lab equity investment in other comprehensive income.
Outlook, commentary, risks and unusual items
- Management said existing cash, cash equivalents and current financial assets were expected to fund operating expenses and capital expenditure for at least the next 12 months. It expected spending and cash burn to remain elevated in 2022 as it expands commercial infrastructure, advances clinical programs and invests in research.
- At the filing date, management anticipated an EMA decision on VYVGART for gMG in the second half of 2022. It also outlined development plans across efgartigimod indications, including ITP, PV, CIDP, BP, myositis, and newer nephrology and autoimmune programs. These are plans and expectations, not assurances of approval or results.
- Clinical, regulatory and commercial execution remain significant risks. The company relies on third parties for clinical trials and manufacturing, including Lonza for drug substance and Vetter for fill-and-finish services; capacity constraints or supply interruptions could affect launches and trials.
- The Russia-Ukraine conflict could disrupt trial recruitment, sample shipment and data auditability, particularly for the ADDRESS trial in pemphigus. The company said it could not assess the timing impact clearly, but did not expect a material impact on overall financial performance at the report date. COVID-19 also posed potential trial, inspection and manufacturing-supply risks.
- Other material risks include failure to sustain VYVGART market acceptance or obtain adequate reimbursement, continued losses and possible future financing needs, foreign-exchange exposure (the company had no currency hedges), and dependence on intellectual-property protection. Accumulated losses were $1.400 billion.
- Unusual financial items include $315.1 million of Janssen-related revenue recognized following termination and a $98.0 million cash outflow for an FDA Priority Review Voucher. The filing also identifies $163.7 million of R&D accruals requiring estimates of vendor progress. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- How much of reported revenue is nonrecurring collaboration accounting versus future royalties, supply revenue or VYVGART product sales.
- VYVGART launch performance, payer coverage, pricing and reimbursement, and the timing and terms of approvals outside the U.S. and Japan.
- Clinical readouts and regulatory progress against management’s stated timelines, including any delays or data limitations in trials affected by the Russia-Ukraine conflict.
- Cash burn, commercialization and pipeline spending, and whether the reported liquidity remains sufficient as costs and launches scale.
- Manufacturing capacity, inventory readiness and facility approvals; year-end inventory was $109.1 million, including $48.8 million awaiting facility approval.
- The estimates behind R&D accruals and collaboration revenue recognition, as well as the effect of currency movements on reported results and cash.